Synopsis

Important fundamental breakthroughs in cancer biology have come from the basic research discovery that defects in the tumor suppressor and DNA repair genes BRCA1/2 genes predispose to breast, ovarian, prostate, and pancreatic cancers. Furthermore, the game-changing synthetic lethality concept for defects with inhibitors to Poly-ADP-Ribose Polymerase 1 (PARP1) is transforming clinical cancer therapy and prompting many new clinical trials. Yet, key gaps in our molecular and mechanistic understanding of therapy efficacy limit our ability to fully harness the insights from DNA damage responses gained so far. In this context, striking ongoing advances in methods and results spanning from molecules to cells and organisms are implicating functionally-important molecular communications coupling the DNA damage response, responses to DNA replication fork instability and DNA-based immune response. Future master keys to cancer biology and advanced therapies will benefit from better defining these distinct cellular stress responses, their mechanistic interconnectivity, and their implications for cancer biology and therapeutic outcomes.

The 6th DNA Repair/Replication Structures & Cancer conference on 14-18 February  2024 will focus on molecular structural and mechanistic insights into dynamic complexes acting in DNA repair, replication, and inflammation and their intersections relevant to advanced cancer therapies. This fundamental information will be pivotal for pioneering research on DNA damage responses as well as for the accurate interpretation of cancer clinical data, design of clinical trials, prognosis, etiology and improving the currently low success rate for oncology drug clinical trials. Informative talks and poster sessions along with vibrant discussions will foster productive interactions, collaborations, and insights. In this conference and this area of science basic research is empowering medical advances and clinical data are unveiling basic relationships in ways that are completely changing how research and translation is being done.

To advance understanding, all presenters are asked to focus on unpublished work, cutting-edge approaches and mechanistic insights. The talks and discussions will seek to aid prediction of biological outcomes and plans to best apply basic research advances for cancer research and treatment. To include late-breakthrough advances and innovative new ideas and methodologies, many talks will be selected from submitted abstracts. Poster sessions are vital part of the conference and contribute greatly to the success of the conference with stimulating and in-depth discussions between junior researchers and well-established international leaders in their field. Meeting attendance is limited, and delegates are encouraged to submit applications and abstracts early to avoid disappointment.

What makes this meeting unique? Professor Ben Van Houten from the University of Pittsburgh says: "This conference stands out as the very best due to the amazing science, great speakers, wonderful venue, and Laura and her teams’ attention to every detail." Professor John Tainer from the University of Texas MD Anderson Cancer Centre says: “This conference makes me want to stand up and cheer because most participants contribute unpublished data and useful discussions that together can identify and fill knowledge gaps with potentially game-changing insights.”

Key Sessions

Sessions will include emerging results and breakthrough methodologies on core topics including:

• Double-Strand Break Repair by homologous recombination, non-homologous end joining, and alternative end joining. 
• Base and Nucleotide Excision Repair and Mismatch Repair 
• Replication stress and replication-associated repair 
• Repair in Mitosis and Meiosis
• DNA and protein-DNA crosslinking repairs
• DDR and inflammation in disease and therapeutics 
• DNA damage response at telomeres 
• Molecular machines in DNA repair regulation
• DDR signalling and pathway choices
• Repair in the chromosome context 
• New repair mechanisms and methodologies  
• Transcription-repair interfaces 

We are excited to continue the tradition from the last conference of including a session dedicated to DDR-based cancer therapeutics. This session will highlight new agents and new combined therapies that have recently entered the clinic and the translational potential of emerging mechanistic knowledge at the repair-replication-inflammation axis.

We are joined by the following incredible speakers:

Ranjit S. Bindra (Yale School of Medicine/Modifi Bio)
TARGETED DNA MODIFICATION: A NEW PARADIGM TO EXPLOIT DDR DEFECTS IN GLIOMA AND BEYOND…
Alejandro Alvarez Quilon (Repare Therapeutics)
EXPLOITING SYNTHETIC LETHALITY TO TARGET GENOME INSTABILITY IN CANCER
Helen Robinson (Artios)
TARGETING THE DDR FOR CANCER THERAPY
Timothy Yap (MD Anderson Cancer Center)
TARGETING ATR IN THE CLINIC: MONOTHERAPY AND COMBINATION STRATEGIES

Student & Postdoc Offer

Take advantage of this fantastic opportunity for students and postdocs! Fully paying 'single' or 'shared' registrants can bring one student or postdoc for only $1,200. Both registration packages include; accommodation for the 14, 15, 16, 17 Feb 2024 (students and postdocs are required to share a room under this offer) and a food and beverage package for the conference period. Once registered, please contact Laura to obtain a special registration link for your student or postdoc.

Plenary Speakers

Simon Boulton (Francis Crick Institute)
CANCER DRIVERS THAT ESTABLISH ALTERNATIVE LENGTHENING OF TELOMERES
Maria Jasin (Memorial Sloan Kettering)
PROTECTING THE GENOME BY HOMOLOGOUS RECOMBINATION

Rising Star Plenary Speaker

Irene Chiolo (University of Southern California)
HETEROCHROMATIN REPAIR MECHANISMS

Confirmed Speakers

Ranjit S. Bindra (Yale School of Medicine/Modifi Bio)
TARGETED DNA MODIFICATION: A NEW PARADIGM TO EXPLOIT DDR DEFECTS IN GLIOMA AND BEYOND…
Cynthia Burrows (University of Utah)
G-QUADRUPLEXES CONNECT BER TO GENE INDUCTION: STRUCTURE & MECHANISM
Junjie Chen (MD Anderson Cancer Center)
REPLICATION STRESS AND CELL CYCLE CHECKPOINT CONTROL
Francesca Cole (MD Anderson Cancer Center)
AGE-DEPENDENT ALTERATIONS IN DNA REPAIR CAUSE CHROMOSOME MIS-SEGREGATION IN MEIOSIS
Alan D'Andrea (Dana-Farber Cancer Institute)
TELOMERE HETEROCHROMATIN ASSEMBLY DURING ALTERNATIVE LENGTHENING OF TELOMERES
Samir Hamdan (KAUST)
HUMAN MATURATION OF OKAZAKI FRAGMENTS IS DYNAMIC, NON-PROCESSIVE AND STRIKINGLY SLOW
Yuan He (Northwestern University)
STRUCTURAL BASIS OF DNA DOUBLE-STRAND BREAK REPAIR BY NHEJ
Karl-Peter Hopfner (Ludwig Maximilian University of Munich)
DNA SENSING AND PROCESSING BY THE Mre11-Rad50 COMPLEX
Stephen Kowalczykowski (University of California, Davis)
MOLECULAR MECHANISM OF CHROMOSOME MAINTENANCE BY HOMOLOGOUS RECOMBINATION
Susan Lees-Miller (University of Calgary)
UNCOVERING DNA-PK DEPENDENT INTERACTIONS
Joseph J. Loparo (Harvard Medical School)
ASSEMBLY AND REMOVAL OF THE NON-HOMOLOGOUS END JOINING REPAIR COMPLEX
John Pascal (University of Montreal)
PARP ENZYMES IN THE DNA DAMAGE RESPONSE AND PARP INHIBITOR MECHANISMS
Lori Passmore (MRC Laboratory of Molecular Biology)
MOLECULAR INSIGHTS INTO DNA CROSSLINK REPAIR
Brian Plosky (Cell Press)
DNA REPAIR AND REPLICATION AND MOLECULAR CELL
Alejandro Alvarez Quilon (Repare Therapeutics)\
EXPLOITING SYNTHETIC LETHALITY TO TARGET GENOME INSTABILITY IN CANCER
Helen Robinson (Artios)
TARGETING THE DDR FOR CANCER THERAPY
Eli Rothenberg (New York University)
DISTINCT MECHANISMS OF PARP INHIBITORS-INDUCED SYNTHETIC LETHALITY AND THERAPEUTIC RESISTANCE
Katharina Schlacher (MD Anderson Cancer Center)
BRCA1/2 FORK PROTECTION FUNCTIONS IN TUMOR SUPPRESSION AND CHEMORESISTANCE
Maria Spies (University of Iowa)
STRUCTURE OF THE DOUBLE-RING OF HUMAN RAD52 AND REPLICATION FORK REMODELLING
Jessica Tyler (Weill Cornell Medicine)
UNUSUAL CHROMATIN INTERACTIONS BY A TARDIGRADE PROTEIN PROTECTING AGAINST OXIDATIVE DNA DAMAGE
Johannes Walter (Harvard Medical School)
AI-DRIVEN INVESTIGATION OF GENOME MAINTENANCE
Steve West (Francis Crick Institute)
RAD51-BCDX2 AND RAD52: CRYO-EM STRUCTURES, FUNCTIONS AND DNA REPAIR MECHANISMS
Dale Wigley (Imperial College London)
NUCLEOSOME FLIPPING DRIVES KINETIC PROOF READING AND PROCESSIVITY OF HISTONE EXCHANGE BY YEAST SWR1 COMPLEX
Scott Williams (NIH)
MOLECULAR MECHANISMS OF TOP2 DNA PROTEIN CROSSLINK RESOLUTION
Rui-Ming Xu (Chinese Academy of Sciences)
MECHANISMS OF HISTONE BINDING AND NUCLEOSOME ASSEMBLY BY CHROMATIN ASSEMBLY FACTOR-1
Wei Yang (NIH)
PROS AND CONS OF DNA REPAIR IN HEREDITARY DISEASES
Timothy Yap (MD Anderson Cancer Center)
TARGETING ATR IN THE CLINIC: MONOTHERAPY AND COMBINATION STRATEGIES
Xiaolan Zhao (Memorial Sloan Kettering Cancer Center)
STRUCTURAL AND FUNCTIONAL INSIGHT INTO A VERSATILE GENOME PROTECTOR COMPLEX Smc5/6

Learning Objectives

Inform basic and clinical researchers on current advances in methodologies, approaches, mechanistic and structural knowledge suitable to understand and predict damage responses and their relationship to cancer. Create optimal formal and informal opportunities to gain new knowledge and to establish fruitful collaborations among key stakeholders in damage responses and cancer research.

Educational Need

This conference will bring together basic and clinical scientists working at the forefront of DNA repair, replication, inflammation, and post-translational modification including PARylation for cancer biology and medicine. Presentations will consider diverse cutting-edge methodologies and integrated approaches to investigate the structures and mechanisms of dynamic protein, chromatin, DNA and RNA complexes. The conference will showcase breakthrough advances and new developments in these areas. It will furthermore provide opportunities for industry and academia to consider and exchange emerging results in this exciting, rapidly advancing arena. The inter-disciplinary nature of the presented work will create strong synergies among participants and outstanding opportunities for exchanging information and developing fruitful collaborations. The cross-disciplinary interactions will be invaluable training for young scientists to work in these and other emerging areas of science.

Target Audience

Academic and industrial researchers (including established and junior principal investigators, postdoctoral fellows and PhD students) interested in DNA damage responses, replication, inflammation, and their intersection with cancer biology and cancer drug discovery. The focus will be the molecular mechanisms of and interfaces controlling damage responses and cancer biology and thereby impacting therapeutic outcomes.

5th DRRSC Photos

4th DRRSC (Fusion's 75th Conference)

Supported By

Silver

Bronze

Media Partners

If you're interested in sponsoring this conference please contact us.